Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one
2. Corlanor
3. Ivabradine
4. S 16257
5. S 16257 2
6. S 16257-2
7. S 162572
8. S 16260 2
9. S 16260-2
10. S 162602
11. S-16257
12. S-16257-2
13. S-16260-2
14. S16257
15. S162572
16. S162602
1. 148849-67-6
2. Ivabradine Hcl
3. Procoralan
4. Corlentor
5. Corlanor
6. Ivabradine (hydrochloride)
7. Tp19837bzk
8. (s)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-benzo[d]azepin-2-one Hydrochloride
9. Ivabradine Hydrochloride [usan]
10. Chebi:85969
11. Amg 998
12. Amg-998
13. S-16257-2
14. 2h-3-benzazepin-2-one, 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-, Hydrochloride (1:1)
15. Ncgc00181343-01
16. 148849-67-6 (hcl)
17. (s)-3-(3-(((3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1h-benzo[d]azepin-2(3h)-one Hydrochloride
18. 3-[3-[[[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one Hydrochloride
19. Ivabradinehydrochloride
20. Ivabradine Hcl (procoralan)
21. S16257
22. Unii-tp19837bzk
23. Corlentor (tn)
24. Corlanor (tn)
25. 2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Hydrochloride (1:1)
26. 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2h-3-benzazepin-2-one Hydrochloride
27. Coralan (tn)
28. Ivabrandine Hydrochloride
29. Ivabradine Monohydrochloride
30. Dsstox_cid_26913
31. Dsstox_rid_82011
32. Dsstox_gsid_46913
33. Schembl23470
34. Mls006010110
35. Ivabradine Hydrochloride- Bio-x
36. Chembl2145077
37. Dtxsid2046913
38. Hy-b0162a
39. 3-[3-[[(7s)-3,4-dimethoxy-7-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one;hydrochloride
40. Bcp05218
41. Tox21_112802
42. Ac-543
43. Ivabradine Hydrochloride (jan/usan)
44. Ivabradine Hydrochloride [mi]
45. Mfcd00929899
46. S2086
47. Ivabradine Hydrochloride [jan]
48. Akos015849582
49. Akos016002249
50. Bcp9000798
51. Ccg-269739
52. Cs-1994
53. Gs-3584
54. Ivabradine Hydrochloride [who-dd]
55. (7,8-dimethoxy 3-(3-(((1s)-(4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one Hydrochloride
56. (s)-3-(3-(((4,5-dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-4,5-dihydro-1h-benzo[d]azepin-2(3h)-one Hydrochloride
57. Bi164596
58. Smr004701246
59. Ivabradine Hydrochloride [ema Epar]
60. Ivabradine Hydrochloride, >=98% (hplc)
61. Am20090729
62. B1360
63. Cas-148849-67-6
64. I0847
65. Ivabradine Hydrochloride [orange Book]
66. D08095
67. 974i008
68. J-008523
69. J-521616
70. Q27158823
71. (+)-s16257
72. 2h-3-benzazepin-2-one, 3-(3-((((7s)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride
73. 2h-3-benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, Monohydrochloride, (s)-
74. 3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one Hydrochloride
75. 3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Hydrochloride
76. 3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1h-3-benzazepin-4-one Hydrochloride3-[3-[[(8s)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,
77. 3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one Hydrochloride
78. 3-{3-[{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2h-3-benzazepin-2-one--hydrogen Chloride (1/1)
79. N-{[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-2-oxo-1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-n-methylpropan-1-aminium Chloride
Molecular Weight | 505.0 g/mol |
---|---|
Molecular Formula | C27H37ClN2O5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 10 |
Exact Mass | 504.2391000 g/mol |
Monoisotopic Mass | 504.2391000 g/mol |
Topological Polar Surface Area | 60.5 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 663 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:
- in adults unable to tolerate or with a contra-indication to the use of beta-blockers
or
- in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
* Symptomatic treatment of chronic stable angina pectoris:
Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:
- in adults unable to tolerate or with a contraindication to the use of beta-blockers
- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.
* Treatment of chronic heart failure:
Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
Symptomatic treatment of chronic stable angina pectoris
Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated:
- in adults unable to tolerate or with a contraindication to the use of beta-blockers
- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.
Treatment of chronic heart failure
Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
* Symptomatic treatment of chronic stable angina pectoris:
Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm.
Ivabradine is indicated:
- in adults unable to tolerate or with a contra-indication to the use of beta-blockers
- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.
* Treatment of chronic heart failure:
Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5. 1)
Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.
Treatment of angina pectoris, Treatment of chronic heart failure, Treatment of coronary artery disease
Treatment of angina pectoris, Treatment of chronic heart failure, Treatment of coronary artery disease
Cardiovascular Agents
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. (See all compounds classified as Cardiovascular Agents.)
C01EB17
C01EB17
C01EB17
C01EB17
C01EB17
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.
Maithri Drugs: Delivering Trusted, High-Quality APIs to 35+ Countries with Innovation, Compliance, and Excellence.
Date of Issue : 2022-11-18
Valid Till : 2025-09-30
Written Confirmation Number : WC-0455
Address of the Firm :
Lewens Labs transforms healthcare with innovative, sustainable, and affordable pharmaceutical solutions worldwide.
Date of Issue : 2023-09-18
Valid Till : 2026-09-17
Written Confirmation Number : WC-0569
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32616
Submission : 2019-10-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27979
Submission : 2014-03-14
Status : Active
Type : II
Registration Number : 230MF10037
Registrant's Address : 13, rue Auguste Desgene(') tais, 76210 Bolbec, FRANCE
Initial Date of Registration : 2018-02-26
Latest Date of Registration :
NDC Package Code : 75852-816
Start Marketing Date : 2014-02-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2009-05-28
Registration Number : 674-1-ND
Manufacturer Name : ORIL INDUSTIRE
Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France
GDUFA
DMF Review : Complete
Rev. Date : 2020-08-12
Pay. Date : 2020-07-22
DMF Number : 32074
Submission : 2017-09-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28658
Submission : 2014-09-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-11-05
Pay. Date : 2018-09-21
DMF Number : 33077
Submission : 2018-09-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33377
Submission : 2018-12-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-02-04
Pay. Date : 2018-12-04
DMF Number : 33368
Submission : 2018-12-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32420
Submission : 2018-02-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32616
Submission : 2019-10-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27979
Submission : 2014-03-14
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-03-01
Pay. Date : 2018-10-19
DMF Number : 33213
Submission : 2018-10-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-01-29
Pay. Date : 2018-11-26
DMF Number : 33107
Submission : 2018-10-31
Status : Active
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Ivabradine, is a small molecule oral blocker of HCN channels, indicated to reduce the risk of hospitalisation for worsening heart failure in adults with stable, symptomatic chronic heart failure.
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Corlanor-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2024
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharma Gains USFDA Final Approval for Ivabradine Tablets, 5 mg and 7.5 mg
Details : Ivabradine, is a small molecule oral blocker of HCN channels, indicated to reduce the risk of hospitalisation for worsening heart failure in adults with stable, symptomatic chronic heart failure.
Product Name : Corlanor-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Details:
USFDA approved generic version of Ivabradine, is a small molecule oral blocker of HCN channels, which is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with certain conditions.
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Ivabradine-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2023
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug
Details : USFDA approved generic version of Ivabradine, is a small molecule oral blocker of HCN channels, which is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with cer...
Product Name : Ivabradine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2023
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Dobutamine Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2022
Lead Product(s) : Ivabradine Hydrochloride,Dobutamine Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2022
Details:
Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 09, 2020
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients
Details : Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 09, 2020
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 07, 2018
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2018
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2018
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2018
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Amgen Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2018
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2018
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Amgen Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2017
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2017
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Amgen Inc | iRhythm Technologies, Inc.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2017
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Amgen Inc | iRhythm Technologies, Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2017
Details:
Undisclosed
Lead Product(s): Ivabradine Hydrochloride,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Amgen Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 02, 2017
Lead Product(s) : Ivabradine Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2017
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
30
PharmaCompass offers a list of Ivabradine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ivabradine Hydrochloride manufacturer or Ivabradine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ivabradine Hydrochloride manufacturer or Ivabradine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Ivabradine Hydrochloride API Price utilized in the formulation of products. Ivabradine Hydrochloride API Price is not always fixed or binding as the Ivabradine Hydrochloride Price is obtained through a variety of data sources. The Ivabradine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ivabradine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ivabradine, including repackagers and relabelers. The FDA regulates Ivabradine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ivabradine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ivabradine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ivabradine supplier is an individual or a company that provides Ivabradine active pharmaceutical ingredient (API) or Ivabradine finished formulations upon request. The Ivabradine suppliers may include Ivabradine API manufacturers, exporters, distributors and traders.
click here to find a list of Ivabradine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ivabradine DMF (Drug Master File) is a document detailing the whole manufacturing process of Ivabradine active pharmaceutical ingredient (API) in detail. Different forms of Ivabradine DMFs exist exist since differing nations have different regulations, such as Ivabradine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ivabradine DMF submitted to regulatory agencies in the US is known as a USDMF. Ivabradine USDMF includes data on Ivabradine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ivabradine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ivabradine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Ivabradine Drug Master File in Japan (Ivabradine JDMF) empowers Ivabradine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Ivabradine JDMF during the approval evaluation for pharmaceutical products. At the time of Ivabradine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Ivabradine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ivabradine Drug Master File in Korea (Ivabradine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ivabradine. The MFDS reviews the Ivabradine KDMF as part of the drug registration process and uses the information provided in the Ivabradine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ivabradine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ivabradine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ivabradine suppliers with KDMF on PharmaCompass.
A Ivabradine written confirmation (Ivabradine WC) is an official document issued by a regulatory agency to a Ivabradine manufacturer, verifying that the manufacturing facility of a Ivabradine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Ivabradine APIs or Ivabradine finished pharmaceutical products to another nation, regulatory agencies frequently require a Ivabradine WC (written confirmation) as part of the regulatory process.
click here to find a list of Ivabradine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ivabradine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ivabradine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ivabradine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ivabradine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ivabradine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ivabradine suppliers with NDC on PharmaCompass.
Ivabradine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ivabradine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ivabradine GMP manufacturer or Ivabradine GMP API supplier for your needs.
A Ivabradine CoA (Certificate of Analysis) is a formal document that attests to Ivabradine's compliance with Ivabradine specifications and serves as a tool for batch-level quality control.
Ivabradine CoA mostly includes findings from lab analyses of a specific batch. For each Ivabradine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ivabradine may be tested according to a variety of international standards, such as European Pharmacopoeia (Ivabradine EP), Ivabradine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ivabradine USP).